President and CEO
Terrance H. Gregg
Terrance H. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen Partners, a private equity firm specializing in the healthcare industry. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.
Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association and serves on the boards of Vasogen, Inc., and LMS Medical Systems.
Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971. In 2003, Mr. Gregg and his wife were recognized by the American Diabetes Association with an award for Outstanding Service in Diabetes Research Funding.
Senior Vice President of Clinical & Regulatory Affairs and Quality Assurance
Andrew K. Balo
Andy Balo Senior Vice President of Clinical & Regulatory Affairs and Quality Assurance, overseeing all of DexCom's clinical trials, statistical analyses, and regulatory submissions. Mr. Balo is widely regarded as an industry expert in regulatory strategies and sits on several FDA panels including cardiovascular, neurological and gastrointestinal as the industry representative. Mr. Balo has been instrumental in bringing several key medical devices to the market including a neurological cooling device, mechanical and tissue-based heart valves, pacemakers, pacing leads, aortic grafts and electrophysiology mapping devices and has gained approval for over thirty PMA and PMA supplements. Prior to joining DexCom, Mr. Balo held positions as Vice President, Regulatory, and Clinical Affairs for INNERCOOL therapies, Inc. and Endocardial Solutions, Inc.
During the 1990s Mr. Balo held several positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company. Mr. Balo holds a BS in Microbiology and Chemistry from the University of Maryland and has studied at UCLA and Stanford.
Vice President, Research and Development
James H. Brauker
James H. Brauker, PhD has served as our Vice President of Research and Development from April 2000 to January 2007, and has served in the same role since March 2008. Dr. Brauker received a BS and an MS from Central Michigan University and a PhD from Michigan State University.
Vice President of International Business Development
Peter Gerhardsson
Peter Gerhardsson joined DexCom as its Vice President of International Business Development in September 2008. For almost thirty years, Mr. Gerhardsson has worked within the pharmaceutical and medical technology business sector. He has extensive experience with diabetes therapies. Mr. Gerhardsson is responsible for developing DexCom's markets outside of the United States. From 1980 to 2000, Mr. Gerhardsson held various sales and marketing roles for Novo Nordisk, including several senior management positions. From 1991 through 1993, Mr. Gerhardsson led the Far East business for Novo Nordisk, managing its fast-growing presence in China, India, South Korea and the Southeast Asian countries. From 1994 - 2000, he was the Managing Director of the Swedish affiliate. After joining MiniMed in 2000, Mr. Gerhardsson was responsible for operations in the Nordic countries, and later was responsible for all European diabetes business units with Medtronic. In 2005, he rejoined Novo Nordisk as Vice President of Corporate Responsibility, including Socio Economics, Stakeholder relations and Social Responsibility programs.
He has served as a board member of the Association of the Swedish Pharmaceutical Industries.
Mr. Gerhardsson has a Bachelor of Science degree from Lund University Sweden and graduate studies in pharmacology from the Medical School of Linkoping University, Sweden. He holds a diploma in marketing and economics from the Executive Foundation of Lund University, Sweden and an EMBA from Stanford University.
Vice President of Marketing
Claudia Graham
Claudia Graham joined DexCom as its Vice President of Marketing in September 2008. Globally recognized as a thought leader in access to diabetes technologies, Claudia is responsible for all product development and commercial marketing activities within DexCom, and is a key liaison with DexCom's co-development partnerships. Prior to joining DexCom, she held multiple positions within Medtronic Diabetes including both Vice President of Global Therapy Access and Vice President of Marketing and Product Development at MiniMed, which was acquired by Medtronic in 2001. Earlier in her career, Claudia was a Director of Marketing for Parke-Davis Pharmaceuticals, a division of Warner Lambert.
She received her PhD from the University of Southern California and her Masters of Public Health from the University of California, Los Angeles. She has served on various national and local boards serving the medical community including the national board of the Medical Marketing Association of America, the community board of directors for the Northridge Hospital Medical Center and the Los Angeles chapter of the Juvenile Diabetes Research Foundation. She has been professionally active in the diabetes community for many years, having served in various appointed and elected positions with the American Diabetes Association (ADA), the Juvenile Diabetes Research Foundation International (JDRF), and the American Association of Diabetes Educators (AADE).
Vice President of Intellectual Property
Laura Johnson
Laura Johnson was promoted to Vice President of Intellectual Property in September 2008. In her previous role as DexCom's Director of Intellectual Property, Ms. Johnson has been instrumental in developing and aligning DexCom’s patent strategy to achieve business goals across a range of development groups and activities. Prior to joining DexCom, Ms. Johnson served as a patent agent at a local law firm, and prior thereto, served in a technical role at Peregrine Systems, Inc. From 1993 to 1999, Ms. Johnson served as a Patent Examiner at the U.S. Patent and Trademark Office in Virginia, examining patents in the technology area of implantable devices. Ms. Johnson holds and BS in Mechanical Engineering from Grove City College in Grove City, PA.
Vice President of Operations
Jeffrey C. Moy
Jeffrey C. Moy was promoted to Vice President of Operations in September 2008. In this capacity, Mr. Moy will be responsible for overseeing DexCom's manufacturing, supply chain, and facility departments. Mr. Moy previously served as DexCom’s Senior Director of Operations since September of 2007. From October 1998 to August 2007, Mr. Moy served as Senior Director and Director of Manufacturing of Biosite, an immunodiagnostics company where he facilitated the scale-up of their manufacturing operations. From 1982 to 1998, Mr. Moy served in various manufacturing roles at Chiron Diagnostics including Process Engineer and Operations Manager.
Mr. Moy received his Bachelor of Science degree in Bioengineering from the University of Pennsylvania and his Master of Engineering degree in Biochemical Engineering from Cornell University.
Senior Vice President of Corporate Affairs
Steven R. Pacelli
Steve Pacelli was promoted to Senior Vice President of Corporate Affairs in July 2007. In this capacity, Mr. Pacelli is charged with overseeing DexCom’s legal, human resources, intellectual property, investor relations, and business development functions. Mr. Pacelli previously served as DexCom’s Vice President of Legal Affairs since April 2006. From March 2003 to April 2006, Mr. Pacelli served as a corporate attorney with Stradling Yocca Carlson & Rauth where he specialized in public and private finance, mergers and acquisitions and general corporate matters for life sciences and technology companies. From February 2001 to March 2003, Mr. Pacelli served as Vice President of Corporate Development, Secretary, and General Counsel of Axcelerant, Inc., a provider of secure managed business network services. From January 2000 to January 2001, Mr. Pacelli served as Vice President, Secretary, and General Counsel of Flashcom, Inc., a provider of consumer broadband DSL services. Mr. Pacelli received a BA from the University of California, Los Angeles, and a JD from the University of Virginia. Mr. Pacelli is a member of the State Bar of California.
Vice President and Chief Financial Officer
Jess Roper
Jess Roper was promoted to Vice President and Chief Financial Officer in March 2008. Mr. Roper joined DexCom in March 2005 as its Director of Finance, and served as its Interim Chief Financial Officer from July 2007 through March 2008. He has over 15 years of financial management and auditing experience. Mr. Roper previously held financial management positions with two other NASDAQ listed companies and one venture funded company, and has been a key participant in two initial public offerings, acquisitions/divestitures, and several equity and debt financings.
Mr. Roper was also an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper holds a BS in Finance, an MS in Corporate Accountancy, and is a certified public accountant in the state of California.
Senior Vice President of Operations
Jorge A. Valdes
Jorge Valdes was promoted to Senior Vice President of Operations in July 2007. Mr. Valdes is responsible for overseeing DexCom’s manufacturing, engineering, and information technology departments. Mr. Valdes previously served as DexCom’s Vice President of Engineering since November 2005. From July 1999 to March 2005, Mr. Valdes served as Vice President of Engineering at Advanced Fibre Communications, or AFC, a provider of broadband access solutions. Mr. Valdes also served as General Manager for the fiber to the premise (FTTP) business unit of AFC beginning in May 2004. From May 1985 until July 1999, Mr. Valdes held positions at Racal-Datacom, Inc., a manufacturer of data communication products, in engineering management, product development and product management. Mr. Valdes received his BS and an MBA from the University of Miami, Florida.
Donald L. Lucas
Don Lucas is the Chairman of the Board and is a 51-year veteran of the venture capital business. He made his first investment in 1957, raising half of the initial equity financing for National Semiconductor Corporation. Don began his career in the corporate finance department of Smith Barney & Co.
Before becoming an individual venture capital investor, Mr. Lucas was a General and Limited Partner of Draper, Gaither & Anderson (DG&A), the first venture capital firm organized on the west coast. DG&A distributed its assets in 1966, realizing an excellent return for its partners. For approximately the last four decades, Mr. Lucas has been actively engaged in venture capital activities both as an individual and as General Partner of Sand Hill Financial Company, a partnership backed by family and friends.
Following his initial investments in several prominent technology companies, Mr. Lucas has become active in such leading companies as Cadence Design Systems, Inc., Macromedia, Inc., PDF Solutions, Inc., and Oracle Corporation.
Mr. Lucas is currently the Chairman of the Board of Directors of Cadence Design Systems, Inc. and is Chairman of the Executive Committee of the Board of Directors of Oracle Corporation. In addition, Mr. Lucas serves as a Director for several other public and private companies. Mr. Lucas is actively involved in educational and community programs. He is a Trustee of the University of Santa Clara. He received his Bachelor of Arts degree from Stanford University and his MBA from Stanford's Graduate School of Business.
Donald A. Lucas
A second-generation venture capitalist, Mr. Donald A. Lucas possesses twenty years of venture capital experience in Silicon Valley. As RWI Ventures’ Founding Managing Member, he has overseen the firm’s investments in over thirty-five private companies. An active participant in Silicon Valley's investment community, Mr. Lucas consistently invests in companies that use technology to provide solutions for existing or emerging markets. He has worked closely with a broad range of technology companies, many of which have become industry standards. Currently, Mr. Lucas serves on the Board of DexCom, Inc. and Khimetrics, Inc. and is a Board Observer at Paracor Medical.
Prior to founding RWI Ventures in 2000, Mr. Donald A. Lucas spent a decade working with his father, Donald L. Lucas, at Sand Hill Financial Company. During Mr. Lucas’s time there, Sand Hill backed numerous technology leaders including Advanced Fibre Communications, Inc., Cadence Design Systems, Inc., Macromedia, Inc., Oracle Corporation and medtech investments including Aksys, Coulter Pharmaceutical and Intuitive Surgical.
Mr. Lucas is an avid fly-fisherman and his favorite lure is the Royal Wulff. He holds a Bachelor of Arts degree in Economics from Santa Clara University.
Sean Carney
Sean Carney is a Managing Director at Warburg Pincus, a private equity firm that has invested over $14 billion worldwide, where he focuses on medical device and financial services investments. Mr. Carney joined Warburg Pincus in 1996 and has served as General Partner since 2001. He currently serves on the board of Bausch & Lomb, Inc. and Arch Capital Group Ltd. Prior to joining Warburg Pincus he was a consultant at McKinsey & Company. He received an AB in economics from Harvard College and an MBA from Harvard Business School.
Terrance H. Gregg
Terrance H. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen-Partners, a private equity firm specializing in the healthcare industry. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith and Nephew and Allergan, Inc.
Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association and serves on the boards of Vasogen, Inc., and LMS Medical Systems.
Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971. In 2003, Mr. Gregg and his wife were recognized by the American Diabetes Association with an award for Outstanding Service in Diabetes Research Funding.
Jonathan Lord
Jonathan Lord, MD serves as Chief Innovation Officer for Humana Inc. In this role, Dr. Lord is responsible for designing innovative health plan products and leading processes that enable people to navigate the healthcare system and support their health needs.
Dr. Lord created Humana's Innovation Center, a functional blend of research, (including consumer research, outcomes research, and predictive science), product design, and consumer experience engineering that is unique to the health benefits industry. His belief in a workplace that encourages exploration, discovery, and personal growth has led to industry-leading products, patent-pending innovations in predictive science, and an aggressive entrepreneurship taking the company into global business relationships.
With 16 years experience in medical administration, he came to Humana from Health Dialog, a Boston-based Internet provider of health information to more than 5 million Americans, where he served as president and became a leader in e-enabled healthcare. Prior to joining Health Dialog, he served as chief operating officer of the American Hospital Association in Washington DC, executive vice president of Anne Arundel Medical Center in Annapolis, MD, and executive vice president of Sun Health in Charlotte, NC.
A board-certified forensic pathologist, Dr. Lord began his medical career in the U.S. Navy, where he spent 11 years on active duty, most recently as director of the Naval Medical Command's Quality Assurance Division in the Office of the Surgeon General. He also served as a consultant and surveyor for the Joint Commission on Accreditation of Health Care Organizations. Dr. Lord has published articles on topics ranging from risk management and quality assurance to prostaglandin biosynthesis. In 2002, he received the Karen Coughlin Individual Disease Management Leadership Award from the Disease Management Association of America (DMAA), honoring his contributions to advancements in the care of the millions of U.S. citizens with chronic disease.
His vision, leadership, and talent for change management have led to appointments to several national boards. As president of the Disease Management Association of America (DMAA) from 2001-2002, Dr. Lord led the organization to restructure its operations, significantly increase its membership and revenues and establish branches in Europe, Asia, and Australia. Also in 2002, he began a three-year term on the National Advisory Council for Healthcare Research and Quality. This prestigious appointment places him among only 21 distinguished healthcare leaders lending advice to the U.S. Secretary of Health and Human Services.
In 2008, Dr. Lord was invited by the Department of Health and Human Services to serve on the Centers for Disease Control and Prevention (CDC) Advisory Committee to the Director. The 21-member committee advises CDC leadership on key strategic issues to assist the agency in fulfilling its vision of health protection and health equity.
Kevin Sayer
Kevin Sayer has served as Chief Financial Officer of Biosensors International Group, Ltd., and as President of Biosensors International USA, a medical technology company developing, manufacturing, and commercializing medical devices used in interventional cardiology and critical care procedures. Prior to joining Biosensors International Group, Mr. Sayer served as an independent healthcare and medical technology industry consultant. From 2004 to 2005, Mr. Sayer was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a company offering clinical reference laboratory services. Mr. Sayer also served as Chief Financial Officer of MiniMed, Inc., a medical technology company focused on insulin pumps for people with diabetes, from May 1994 until its acquisition by Medtronic, Inc. in August 2001. Mr. Sayer is a Certified Public Accountant and received his Master's Degree in Accounting and Information system concurrently with a Bachelor's Degree in Accounting, both from Brigham Young University.
Jay Skyler, MD
Dr. Jay Skyler is a Professor of Medicine, Pediatrics, & Psychology at the University of Miami, Miami, Florida, in the Division of Endocrinology, Diabetes, & Metabolism in the Department of Medicine, of which he was the Director from 2000 to 2004; and Associate Director for Academic Programs in the Diabetes Research Institute. He is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing "algorithms" for patient adjustment of insulin doses.
Dr. Skyler is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding Editor-in-Chief of Diabetes Care, and currently is Scientific Editor of International Diabetes Monitor and is Associate Editor of Diabetes Technology & Therapeutics.
He has a bachelor of science degree from Pennsylvania State University and a doctor of medicine degree from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.
Vice President of Strategic Affairs
Richard C. Yang
Richard C. Yang was promoted to Vice President of Strategic Affairs in September 2008. Mr. Yang is responsible for the management and output of the global strategic planning function. Mr. Yang previously served as DexCom's Director of Hospital Technologies.
Prior to joining DexCom, Mr. Yang was the Marketing Director at Pegasus Biologics that grew a startup into a market leader with a diversified product portfolio in Orthopedics and Wound Management. For ten years, Mr. Yang held positions of increasing responsibility with medical device companies including Integra LifeSciences (Orthopedics Business Unit), Karl Storz Endoscopy (Neurosurgery Business Unit) and Medtronic Diabetes where he was responsible for product management and business development roles. While at Medtronic Diabetes, Mr. Yang managed their entry and growth in Asia Pacific. Mr. Yang received a Bachelor of Science degree in Biological Sciences at the University of California, Irvine.